Related Experiment Video
Updated: Jul 8, 2026
07:53
Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study
Published on: August 16, 2019
Efficient factor VIII affinity purification using a small synthetic ligand.
1Center of Integrated Protein Science, Munich, at Department Chemie, Lehrstuhl II für Organische Chemie, Technische Universität München, Garching, Germany.
Journal of Thrombosis and Haemostasis : JTH
|January 16, 2008
Summary
A novel peptidomimetic ligand, L4, effectively purifies coagulation factor VIII (FVIII) with high yield and purity. This stable, non-toxic ligand offers a cost-effective alternative to current antibody-based methods for FVIII production.
Area of Science:
- Biochemistry
- Biotechnology
- Protein Purification
Background:
- Current coagulation factor VIII (FVIII) purification methods are costly and inefficient.
- Immunoaffinity chromatography uses unstable antibodies, leading to product contamination.
- Existing octapeptide ligands have limited protease resistance.
Purpose of the Study:
- Develop and assess a novel, stable ligand for FVIII purification.
- Overcome limitations of existing FVIII purification techniques.
Main Methods:
- Screened peptide ligands for FVIII binding using a microbead assay.
- Utilized L4-ligand-coated Toyopearl resin for FVIII purification from cell-conditioned medium.
- Assessed ligand proteolytic stability and cytotoxicity.
Main Results:
- Developed a stable, non-toxic peptidomimetic ligand (L4) with high FVIII affinity.
- Achieved high purity FVIII isolation using L4-coated resin.
- Demonstrated 89% column retention with mild elution conditions.
Conclusions:
- Ligand L4 provides a superior alternative to antibody-based FVIII purification.
- L4 offers straightforward synthesis, reduced cost, and enhanced safety.
- This method is suitable for both laboratory and industrial FVIII production.
